In prostate cancer, end points that reliably portend prognosis and treatment benefit (surrogate end points) can accelerate therapy development. Although surrogate end point candidates have been ...

The FDA's accelerated approval pathway often relies on surrogate endpoints, raising concerns about their predictive value for clinical benefits. Nononcology accelerated approvals from 2013 to 2024 ...